3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
18
Neoplasms
11
Venous Thrombosis
9
Pulmonary Embolism
9
Thrombosis
5
Multiple Myeloma
4
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Intracranial Thrombosis
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Upper Extremity Deep Vein Thrombosis
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Mesenteric Ischemia
1
Leukemia
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Interventions
Gemcitabine
92
Cisplatin
70
Oxaliplatin
37
Capecitabine
37
durvalumab
29
Fluorouracil
26
pembrolizumab
24
Leucovorin
22
S 1 (combination)
18
Nivolumab
13
Irinotecan
13
Bevacizumab
13
lenvatinib
12
tremelimumab
10
apatinib
8
Trastuzumab
7
Injections
7
Albumin-Bound Paclitaxel
7
130-nm albumin-bound paclitaxel
7
Paclitaxel
6
Immune Checkpoint Inhibitors
6
Docetaxel
6
titanium silicide
5
surufatinib
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Biliary Tract Neoplasms
×
apixaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled